Equities research analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to report earnings of ($0.46) per share for the current quarter, according to Zacks. Four analysts have made estimates for Strongbridge Biopharma’s earnings. The lowest EPS estimate is ($0.50) and the highest is ($0.42). Strongbridge Biopharma reported earnings per share of ($0.35) in the same quarter last year, which would indicate a negative year over year growth rate of 31.4%. The company is scheduled to report its next quarterly earnings results on Tuesday, November 13th.

On average, analysts expect that Strongbridge Biopharma will report full-year earnings of ($1.72) per share for the current fiscal year, with EPS estimates ranging from ($1.88) to ($1.56). For the next financial year, analysts expect that the firm will post earnings of ($1.34) per share, with EPS estimates ranging from ($1.49) to ($1.18). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover Strongbridge Biopharma.

Strongbridge Biopharma (NASDAQ:SBBP) last issued its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.41. The firm had revenue of $4.30 million during the quarter, compared to analyst estimates of $4.53 million.

A number of research analysts recently weighed in on the company. BidaskClub upgraded Strongbridge Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, June 19th. Zacks Investment Research upgraded Strongbridge Biopharma from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a report on Wednesday, August 15th. ValuEngine cut Strongbridge Biopharma from a “buy” rating to a “hold” rating in a report on Friday, June 22nd. Janney Montgomery Scott assumed coverage on Strongbridge Biopharma in a report on Thursday, June 28th. They issued a “buy” rating on the stock. Finally, JMP Securities lifted their target price on Strongbridge Biopharma from $10.00 to $16.00 and gave the company a “market outperform” rating in a report on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $14.75.

Strongbridge Biopharma stock remained flat at $$5.00 during midday trading on Friday. The company had a trading volume of 610,831 shares, compared to its average volume of 416,233. Strongbridge Biopharma has a 52-week low of $3.85 and a 52-week high of $9.25. The firm has a market capitalization of $226.54 million, a PE ratio of -3.45 and a beta of 0.80. The company has a quick ratio of 6.38, a current ratio of 6.46 and a debt-to-equity ratio of 8.76.

In other news, major shareholder Associates L.L.C. Cdk bought 70,000 shares of Strongbridge Biopharma stock in a transaction that occurred on Monday, July 30th. The shares were purchased at an average price of $4.66 per share, for a total transaction of $326,200.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders purchased 910,795 shares of company stock worth $4,430,231 in the last quarter. 4.20% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of SBBP. Laurion Capital Management LP acquired a new position in shares of Strongbridge Biopharma during the second quarter worth about $101,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Strongbridge Biopharma during the second quarter worth about $110,000. Cubist Systematic Strategies LLC acquired a new position in shares of Strongbridge Biopharma during the second quarter worth about $130,000. Jane Street Group LLC acquired a new position in shares of Strongbridge Biopharma during the second quarter worth about $154,000. Finally, Citadel Advisors LLC acquired a new position in shares of Strongbridge Biopharma during the first quarter worth about $166,000. Institutional investors own 66.89% of the company’s stock.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

Featured Article: What are the reasons investors use put options?

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.